• Teigen to advocate for the importance of type 1 diabetes screening after son's diagnosis was uncovered during an unexpected medical emergency
• Screen For Type 1 movement continues momentum into year two with the goal of encouraging people to screen early; just one blood test can spot type 1 diabetes before symptoms occur

MORRISTOWN, N.J., April 15, 2025 /PRNewswire/ -- Sanofi, a leader in diabetes care, welcomes author, entrepreneur, and mom Chrissy Teigen as its new celebrity spokesperson for the Screen For Type 1 movement. The partnership, announced on T1D Day, comes as the Screen For Type 1 movement strives to expand diabetes education nationwide, raising awareness of the benefits of early risk detection.

Teigen has a personal connection to type 1 diabetes. Her son, Miles, was diagnosed unexpectedly at the age of six and ended up in the hospital due to complications from the disease – an experience shared by many individuals and families. In fact, each year, around 64,000 Americans are diagnosed with type 1 diabetes; as many as 40% of people are unaware they have the disease until they experience a life-threatening event that requires hospitalization. In her role with Screen For Type 1, Teigen will advocate for early type 1 diabetes risk detection, sharing her personal story to help families understand why screening is so important.

Chrissy Teigen

Author, entrepreneur, and mom

"Our family knew nothing about type 1 diabetes prior to 2024 – and when I say nothing, I mean absolutely nothing. We were confused and scared when Miles was first diagnosed. Miles is a warrior – a type 1 diabetes warrior – and we are learning together every day how to help him manage this disease, but there is no doubt in my mind that knowing in advance would have made a positive impact for Miles, me, and our entire family. I want everyone to hear me when I say: stay proactive and talk to your doctor about getting yourself or your loved ones screened for type 1 diabetes today!"

Nadia Fontaine

Head, US Autoimmune Type 1 Diabetes Franchise

"It's unacceptable that many people are still finding out about a type 1 diabetes diagnosis only when serious complications arise. We're energized to partner with Chrissy Teigen on the Screen For Type 1 movement and believe her story will strongly resonate with families and underscore the importance of early risk detection."

Anyone can screen for type 1 diabetes, which consists of just one blood test that identifies whether a person has autoantibodies related to type 1 diabetes before symptoms even appear. While type 1 diabetes cannot be prevented, it can be detected early through autoantibody screening, before serious health complications may occur, which may give people more time to prepare and plan for the future.

People can visit ScreenForType1.com for helpful tools and resources about early screening options. Sanofi encourages people interested in learning more about screening for type 1 diabetes to speak to their doctor.

Teigen and other social media personalities who are participating in the Screen For Type 1 movement are paid spokespeople for Sanofi.

About Sanofi 

We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people's lives. Our team, across the world, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions.

Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY

Media Relations 

Evan Berland | + 1 215 432 0234 | This email address is being protected from spambots. You need JavaScript enabled to view it. 

Investor Relations

Thomas Kudsk Larsen |+44 7545 513 693 | This email address is being protected from spambots. You need JavaScript enabled to view it.
Alizé Kaisserian | +33 6 47 04 12 11 | This email address is being protected from spambots. You need JavaScript enabled to view it.
Felix Lauscher | +1 908 612 7239 | This email address is being protected from spambots. You need JavaScript enabled to view it.
Keita Browne | +1 781 249 1766 | This email address is being protected from spambots. You need JavaScript enabled to view it.
Nathalie Pham | +33 7 85 93 30 17 | This email address is being protected from spambots. You need JavaScript enabled to view it.
Tarik Elgoutni | +1 617 710 3587 | This email address is being protected from spambots. You need JavaScript enabled to view it.
Thibaud Châtelet | +33 6 80 80 89 90 | This email address is being protected from spambots. You need JavaScript enabled to view it.
 Yun Li | +33 6 84 00 90 72 | This email address is being protected from spambots. You need JavaScript enabled to view it.

Sanofi Forward-Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates regarding the marketing and other potential of the product, or regarding potential future revenues from the product. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans", and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, unexpected regulatory actions or delays, or government regulation generally, that could affect the availability or commercial potential of the product, the fact that product may not be commercially successful, the uncertainties inherent in research and development, including future clinical data and analysis of existing clinical data relating to the product, including post marketing, unexpected safety, quality or manufacturing issues, competition in general, risks associated with intellectual property and any related future litigation and the ultimate outcome of such litigation, and volatile economic and market conditions, and the impact that global crises may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2024. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

All trademarks mentioned in this press release are the property of the Sanofi group.